FAP and neoplasm: Importantly, dual sequential treatment with FAP-CAR T cells overcomes the negative effects of the TME on Meso-CAR T cells or immune checkpoint blockade in pre-clinical PDAC models, resulting in significant inhibition of tumor growth in multiple PDAC models by anti-PD-1 and by Meso-CAR T cells.